Pharmaceuticals News and Research

RSS

New Penn Center for Orphan Disease Research and Therapy

The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania announces the launching of a first-of-its-kind interdisciplinary center focused on discovering novel treatments for orphan diseases.

27 Jul 2011

Wolters Kluwer announces divestment of Pharma business

Wolters Kluwer, a market leader in the professional health content and clinical decision support market, today announced a plan to divest its Pharma-related business. The company is well-positioned to benefit from healthcare reform trends globally to support the Health division's growth strategy.

27 Jul 2011

Teva second quarter net sales increase 11% to $4.2 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2011.

27 Jul 2011

Nano-emulsion shows promise for Viagra patch

Sildenafil citrate, commonly known as Viagra, is currently the first choice drug for erectile dysfunction but despite its success oral delivery of the drug is hampered by numerous side effects, the long delay before it starts working and the short amount of time it lasts. Researchers in Egypt think they may have a solution via nanotechnology.

27 Jul 2011

Male sex hormones can protect men from inflammatory diseases

It's all down to the testosterone: men are usually more muscular than women, they have deeper voices and more body hair. And - men are less susceptible to inflammatory diseases and allergies than women. This is also due to the male sex hormones as pharmacists at the Friedrich Schiller University Jena have shown in a recent study.

27 Jul 2011

EMA accepts to evaluate Vanda's MAA for oral iloperidone tablets

Vanda Pharmaceuticals Inc. announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets.

27 Jul 2011

Lipid-based nanocarrier can improve cancer treatments

Scientists seeking to improve cancer treatments have created a tiny drug transporter that maximizes its ability to silence damaging genes by finding the equivalent of an expressway into a target cell.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

Viewpoints: The effects of the debt debate; Medicare's birthday; N.Y. drug plan

In the scramble to cut the nation's debt burden, President Obama, congressional Democrats and even some Republicans have proposed squeezing money out of Medicare by changing the way it pays for prescription drugs.

27 Jul 2011

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company's lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.

27 Jul 2011

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

27 Jul 2011

NeurOp receives NIH grant to support research program for ischemia

NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support its research program for ischemia.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Less smokers but more drug addicts: Australian population survey

...

26 Jul 2011

Volunteers needed in worldwide study to help people breathe easier

Australian sufferers of chronic obstructive pulmonary disorder (COPD), one of the most important causes of breathlessness and difficulty performing tasks of normal daily life, have the opportunity to participate in a worldwide study, starting this month, assessing a potential new treatment.

26 Jul 2011

Abbott announces research confirming presence of lutein in key regions of the infant brain

Preliminary new research demonstrates for the first time that lutein, an important phytonutrient (plant-based nutrient) that supports eye health, is the predominant carotenoid present in key areas of the infant brain, including areas that regulate overall brain function, cognition, vision, hearing and speech. This new research, supported by Abbott, was presented by Elizabeth Johnson, PhD, a scientist in the Carotenoids and Health Laboratory at Tufts University, at the 16th International Symposium on Carotenoids, in Krakow, Poland.

26 Jul 2011

Watson second quarter net revenue increases 24% to $1.1 billion

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the second quarter ended June 30, 2011, an increase of 24 percent when compared to $875.3 million in the second quarter 2010.

26 Jul 2011

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and six months ended June 30, 2011.

26 Jul 2011

Taro second quarter net sales increase 14.2% to $111.6 million

Taro Pharmaceutical Industries Ltd. today provided unaudited financial results for the quarter and year to date periods ended June 30, 2011.

26 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011